retatrutide triple agonist glp-1 gip glucagon phase 2 results Efficacy and safety of retatrutide, a GIP, GLP-1, and receptor agonist, in people with type diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Retatrutide: The "Triple G" Peptide

Fortunately, theres a therapeutic peptide that keeps senescence under control and stops the build-up of too many non-dividing cells: FOXO4-DRI

A recent analysis of 48 studies found that after one year of getting off GLP-1s, patients regained 60% of their original weight loss

It is studied for antioxidant activity, detoxification pathways, immune response, and cellular repair mechanisms

More interestingly, these investigators showed that gemtigliptin in combination with another anti-diabetic compound, but belonging to a different class (biguanides), Metformin (Kim et al., 2018a), exerts a stronger adverse effect on TC cells in vitro